Panacea Biotec supplies first shipment of Sputnik V’s second component produced in India

Doses of the second component of Sputnik V have been manufactured at the Panacea Biotec’s state-of-the-art vaccine manufacturing facility in Himachal Pradesh

  • Updated On Sep 7, 2021 at 12:45 PM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
The Russian Direct Investment Fund (RDIF) and Panacea Biotec have announced the supply of the first shipment out of one million doses of the second component (human adenovirus serotype 5) of the Russian Sputnik V coronavirus vaccine manufactured by Panacea Biotec for sale in India.

"This is the first batch of the second component produced and supplied by the company in India. Doses of the second component of Sputnik V have been manufactured at Panacea Biotec’s state-of-the-art vaccine manufacturing facility in Himachal Pradesh. The company received necessary clearance from the Central Drug Laboratories (CDL), Kasauli on 31st August, 2021," the company said in a statement.

Advt
It also notified that the full-scale production of Sputnik V started at Panacea Biotec’s facilities this summer. Facilities comply with GMP standards and are prequalified by the World Health Organization (WHO).

As per the statement, the batch will be distributed in India through a partner of RDIF and Panacea Biotec-Dr Reddy’s Laboratories.

Speaking in this regard, Dr Rajesh Jain, Managing Director, Panacea Biotec, said, “Panacea Biotec is pleased to have successfully produced and dispatched the first batch of Component II (Ad5) of Sputnik V vaccine. More batches are currently under production at our manufacturing facility in Himachal Pradesh.”
  • Published On Sep 7, 2021 at 12:45 PM IST
Be the first one to comment.
Comment Now

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App